Launching a Biotech in 2020: 3 Challenges Faced, and 3 Avoided
Launching a Biotech in 2020: 3 Challenges Faced, and 3 Avoided
An inside look on the launch of Elevation Oncology during 2020 and the COVID-19 pandemic, and the lessons we’ll carry forward into 2021!
Read More
Infographic: PDX models and precision oncology
What are PDX models, and why are they important to precision medicine? We break down the term in this infographic!
Read More 
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
Read More NRG1 fusions, a (PDX) model challenge
With the advent of the ‘precision oncology’ movement, the success of biomarker-driven targeted therapies has fundamentally changed our approach to drug development and treatment selection.
Read More EORTC-NCI-AACR 2020
The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
Read More 
Elevation Oncology Announces the Presentation of Preclinical Data on the Specific Inhibition of HER3 to Block NRG1 Fusion Signaling
Presentation of data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Read More IASLC North America Conference on Lung Cancer 2020
Trial in Progress: the CRESTONE study with Dr. David Spiegel
Read More 